Atorvastatin and ischemic stroke: Mechanisms and therapeutic applications
Clicks: 8
ID: 313635
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
2.1
/100
8 views
2 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #16 of 40 articles by views in Journal of Neuropathology & Experimental Neurology
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Stroke is a leading cause of death and disability, affecting approximately 13.7 million people worldwide and causing 5.5 million deaths annually. Effective treatment options for ischemic stroke are still limited and existing clinical interventions have limitations such as the time window for treatment. Therefore, research is needed to find complementary therapies that can reduce the complications of stroke or prevent its occurrence. Atorvastatin is an oral medication used to lower lipid levels via competitive inhibition of 3-hydroxy-3-methyl-glutaryl-CoA (HMG-CoA) reductase, which results in decreased cholesterol production. Much evidence demonstrates the effectiveness of atorvastatin in stroke but few studies have specifically examined its neuroprotective effects and the underlying mechanisms. This review focuses on the neuroprotective actions of atorvastatin in preclinical and clinical studies and provides an updated discussion on molecular mechanisms contributing to these possible effects in ischemic stroke. We hope that this review will help readers gain a better understanding of the roles of atorvastatin in cerebral ischemic stroke and provide more comprehensive insights for basic research and novel strategies for the treatment of patients with stroke.
| Reference Key |
openalex_W7161133524
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Peyman Esmaili‐Shahzade‐Ali‐Akbari, Abolfazl Azami Tameh, Houman Parsaei, Shirin Barati, Zeinab Vahidinia |
| Journal | Journal of Neuropathology & Experimental Neurology |
| Year | 2026 |
| DOI |
10.1093/jnen/nlag009
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.